(HealthDay)—Metastasis-free survival is significantly longer among men with nonmetastatic, castration-resistant prostate cancer treated with darolutamide versus placebo, according to a phase 3 study published online Feb. ...
5 hours ago
0
1
In Europe, prostate cancer is the most common type of cancer among men with an incidence greater than 100 cases per 100,000 individuals. Furthermore, it is currently the second most common cause of cancer-related deaths among ...
Feb 18, 2019
0
2
Cancer researchers have long known that prostate cancer tends to be more common, more aggressive and more resistant to existing treatments in African-Americans than in Caucasian-Americans, but they're only beginning to understand ...
Feb 18, 2019
0
21
Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have failed, according to early results from a clinical trial led by investigators ...
Feb 15, 2019
0
2
A new recipe for pills and tablets that includes oils and tiny porous particles can help your body absorb medicines more than twice as effectively.
Feb 13, 2019
0
1
(HealthDay)—Many more American men are now saying no to surgery for low-risk prostate cancer, and choosing to monitor the disease instead, a new study finds.
Feb 12, 2019
0
1
It used to be a statistical fact that African-American men fared worse than whites when battling prostate cancer.
Feb 12, 2019
0
6
Many men with low-risk prostate cancer who most likely previously would have undergone immediate surgery or radiation are now adopting a more conservative "active surveillance" strategy, according to an analysis of a new ...
Feb 11, 2019
0
5
An old military tactic, widely used in Roman and medieval times, is now being put to good use in cancer research.
Feb 07, 2019
0
407
A team of researchers from the Icahn School of Medicine at Mount Sinai and Keck School of Medicine at the University of Southern California (USC) have developed a novel machine-learning framework that distinguishes between ...
Feb 07, 2019
0
35
